February 4, 2019 | Case study, Conference Live
How we helped track and evaluate conference performance over time across multiple international events
Our client planned to have a significant presence at key global conferences over the course of a year. Find out how we effectively monitored perceptions of their brand across different regions over time.
The challenge:
Our client was developing a portfolio for the treatment of a chronic neurodegenerative disease and planned to have a significant presence at key neuroscience conferences over the coming year. With conferences being a considerable investment, they wanted to understand:
How various aspects of their presence and presentations n(vs competitors) at each event impacted their target.
The solution:
Using our proprietary tool Conference Live, we conducted research at multiple conferences across EU and US for a year. For each event, we recruited a sample of Neurologists, Psychiatrists, and Physicians. As the aim of the research was to measure perceptions over time, we recruited new respondents for each conference to capture ‘current’ perceptions and not those with views potentially affected by participation in earlier surveys.
Before, during and after each event we used online and mobile surveys to capture perceptions around the therapy area, companies engaging in this space, and of our client as an upcoming player. This allowed for a comparative analysis and a depiction of any changes over time.
To gain insight into the key aspects of physicians’ experiences, we administered a series of in-the-moment mini-questionnaires evaluating visits to a range of exhibition stands and the main scientific presentations of the day as well as a number of smaller poster presentations.
The outputs:
By conducting research over the course of several events, our client was able to effectively monitor the awareness and knowledge of their upcoming portfolio over time and learn how this differed in each region. Furthermore, they were able to track any changes in physicians’ perceptions of them becoming a key player, with clear signals as to which had been the most pivotal presentations and papers that shaped opinion.
Real-time insights meant almost immediate feedback on the initiatives they ran at each conference including the effectiveness of papers, posters, exhibition space, and marketing messages. In addition to identifying the most successful initiatives, we were also able to provide further insight into ways in which they could improve any that were less successful at future events.
This content was provided by Inizio
Latest Content from Inizio
Living with UC is a quantitative study conducted online amongst 325 patients, including both adult and paediatric patients diagnosed with ulcerative colitis in 5 EU markets (France, Germany, Italy, Spain...
We look for bright and inquisitive people who want to learn in a company that's pushing the boundaries of pharmaceutical market research
Pegasus, an Ashfield company, part of UDG Healthcare plc, is delighted to have won the prestigious Consultancy of the Year award at the 2016 Communiqué Awards in London. The judges...
Published in eyeforpharma July 2016 by Rachel Howard
Pegasus has expanded its pharma & life sciences senior team by appointing a new Associate Director and promoting two members of the existing team to Account Directors.
Our latest HIV infographic, taken from data collected from syndicated tracking study Therapy Watch, reveals that more than 3 in 5 naive or switch patients are currently treated with a STR (single...
As predicted, the vaccine market in emerging and developing countries has continued to expand. While the global vaccine market is expected to grow at around 12% annually over the next...
Tuesday 19th July 15:00 BST/10:00 EDT/16:00 CEST
The patient journey is changing. Patients are now much more educated and engaged. They have access to information and want to be involved in decisions around their treatment programme. Technology...
The challenge:Our client needed to understand moleculardiagnostic testing growth opportunities for a new biomarker in oncology. They wanted to understand the current market landscape, identify potential leverage points that would maximise use of the biomarker...
